Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06031441 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 65 | Genentech, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 |
| clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 3 | Jul 28, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT05840224 | Study of GS-4528 in Adults With Solid Tumors | active not recruiting | Phase 1 | 182 | Gilead SciencesINDUSTRY | 6 | Jul 27, 2026 | clinicaltrials |
| NCT06658353 | Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors | recruiting | Phase 3 | 54 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07727317 | Evaluate the Diagnostic Efficacy and Safety of INR 202 PET/CT Imaging in Participants With Advanced Solid Tumors | not yet recruiting | N/A | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT03223753 | Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer | completed | Phase 3 | 299 | Children's Oncology GroupNETWORK | 2 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT05826600 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | terminated | Phase 1 / Phase 2 | 68 | iOmx Therapeutics AGINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT06445517 | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 60 | InSilico Medicine Hong Kong LimitedINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06929260 | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z | terminated | Phase 1 | 1 | AstraZenecaINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07002203 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | recruiting | Phase 1 / Phase 2 | 10 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07098299 | Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies | recruiting | Phase 1 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07362888 | First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Adcendo ApSINDUSTRY | 2 | Jul 24, 2026 | clinicaltrials |
| NCT07460375 | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 191 | LigaChem Biosciences, Inc.INDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | recruiting | Phase 2 | 18 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05719558 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | recruiting | Phase 1 | 798 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 570 | Incyte CorporationINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | terminated | Phase 1 | 5 | QSAM Therapeutics, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06234098 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Alyssum TherapeuticsINDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06719362 | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | recruiting | Phase 1 | 110 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06724042 | Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 159 | InSilico Medicine Hong Kong LimitedINDUSTRY | 0 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 132 | MOMA TherapeuticsINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | recruiting | Phase 2 | 14 | AmgenINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | recruiting | Phase 1 | 180 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07606287 | Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital | not yet recruiting | N/A | 4,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | recruiting | Phase 1 | 710 | Incyte CorporationINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | recruiting | Phase 1 | 63 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07718581 | HMPL-A830 in Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01591356 | EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors | active not recruiting | Phase 1 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02421380 | Characterization of Hyperpolarized Pyruvate MRI Reproducibility | recruiting | N/A | 109 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04447651 | Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)(PRISMM) | active not recruiting | — | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 291 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2026source: clinicaltrials